• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Interleukin-17: A potential therapeutic target in COVID-19.

作者信息

Mendoza Vicky M Montaño

机构信息

Faculty of Medicine, University of Antioquia, Medellin 050010, Antioquia, Colombia; Reproduction Group, University of Antioquia, Medellin 050010, Antioquia, Colombia.

出版信息

J Infect. 2020 Aug;81(2):e136-e138. doi: 10.1016/j.jinf.2020.05.072. Epub 2020 Jun 3.

DOI:10.1016/j.jinf.2020.05.072
PMID:32504739
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7834707/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/708f/7834707/eeaa4fdb8886/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/708f/7834707/eeaa4fdb8886/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/708f/7834707/eeaa4fdb8886/gr1_lrg.jpg

相似文献

1
Interleukin-17: A potential therapeutic target in COVID-19.白细胞介素-17：新冠病毒病的一个潜在治疗靶点。
J Infect. 2020 Aug;81(2):e136-e138. doi: 10.1016/j.jinf.2020.05.072. Epub 2020 Jun 3.
2
REPLY TO: Interleukin-17: a potential therapeutic target in COVID-19.回复：白细胞介素-17：新冠病毒病的一个潜在治疗靶点。
J Infect. 2020 Sep;81(3):e37-e38. doi: 10.1016/j.jinf.2020.06.063. Epub 2020 Jun 29.
3
Why judiciously timed anti-IL 6 therapy may be of benefit in severe COVID-19 infection.为何适时进行的抗白细胞介素6治疗可能对重症COVID-19感染有益。
Autoimmun Rev. 2020 Jul;19(7):102563. doi: 10.1016/j.autrev.2020.102563. Epub 2020 May 5.
4
Contrasting evidence for corticosteroid treatment for coronavirus-induced cytokine storm.关于皮质类固醇治疗冠状病毒诱导的细胞因子风暴的对比证据。
Hong Kong Med J. 2020 Jun;26(3):269-271. doi: 10.12809/hkmj208517. Epub 2020 Jun 5.
5
Letter to the Editor in response to the article "Could IL-17 represent a new therapeutic target for the treatment and/or management of COVID-19-related respiratory syndrome?".致编辑的信：回应文章《白细胞介素-17能否成为治疗和/或管理新冠病毒相关呼吸综合征的新治疗靶点？》
Pharmacol Res. 2020 Aug;158:104933. doi: 10.1016/j.phrs.2020.104933. Epub 2020 May 20.
6
Mast cells activated by SARS-CoV-2 release histamine which increases IL-1 levels causing cytokine storm and inflammatory reaction in COVID-19.SARS-CoV-2 激活的肥大细胞释放组织胺，增加白细胞介素-1 水平，导致 COVID-19 中的细胞因子风暴和炎症反应。
J Biol Regul Homeost Agents. 2020;34(5):1629-1632. doi: 10.23812/20-2EDIT.
7
COVID-19, Mast Cells, Cytokine Storm, Psychological Stress, and Neuroinflammation.COVID-19、肥大细胞、细胞因子风暴、心理压力和神经炎症。
Neuroscientist. 2020 Oct-Dec;26(5-6):402-414. doi: 10.1177/1073858420941476. Epub 2020 Jul 18.
8
Extracorporeal cytokine adsorption as an alternative to pharmacological inhibition of IL-6 in COVID-19.体外细胞因子吸附作为COVID-19中白细胞介素-6药物抑制的替代方法。
Crit Care. 2020 Aug 20;24(1):514. doi: 10.1186/s13054-020-03238-1.
9
Histamine release theory and roles of antihistamine in the treatment of cytokines storm of COVID-19.组胺释放理论及抗组胺药在治疗新型冠状病毒肺炎细胞因子风暴中的作用
Travel Med Infect Dis. 2020 Sep-Oct;37:101874. doi: 10.1016/j.tmaid.2020.101874. Epub 2020 Sep 3.
10
Cytokine storm syndrome in severe COVID-19.重症新型冠状病毒肺炎中的细胞因子风暴综合征
Autoimmun Rev. 2020 Jul;19(7):102562. doi: 10.1016/j.autrev.2020.102562. Epub 2020 May 3.

引用本文的文献

1
Microbiome dysbiosis in SARS-CoV-2 infection: implication for pathophysiology and management strategies of COVID-19.新型冠状病毒感染中的微生物群失调：对2019冠状病毒病病理生理学和管理策略的影响
Front Cell Infect Microbiol. 2025 Apr 22;15:1537456. doi: 10.3389/fcimb.2025.1537456. eCollection 2025.
2
Effects of Tocilizumab on Inflammation and Iron Metabolism in Critically Ill Patients with COVID-19.托珠单抗对COVID-19危重症患者炎症及铁代谢的影响
Pharmaceutics. 2023 Feb 14;15(2):646. doi: 10.3390/pharmaceutics15020646.
3
Biological sex and age-related differences shape the antiviral response to SARS-CoV-2 infection.

本文引用的文献

1
Effective treatment of severe COVID-19 patients with tocilizumab.托珠单抗治疗重症 COVID-19 患者有效。
Proc Natl Acad Sci U S A. 2020 May 19;117(20):10970-10975. doi: 10.1073/pnas.2005615117. Epub 2020 Apr 29.
2
COVID-19: risk for cytokine targeting in chronic inflammatory diseases?COVID-19：慢性炎症性疾病中细胞因子靶向治疗的风险？
Nat Rev Immunol. 2020 May;20(5):271-272. doi: 10.1038/s41577-020-0312-7.
3
The pathogenesis and treatment of the `Cytokine Storm' in COVID-19.新型冠状病毒病中“细胞因子风暴”的发病机制与治疗。
生物性别和年龄相关差异塑造了对SARS-CoV-2感染的抗病毒反应。
Heliyon. 2023 Jan;9(1):e13045. doi: 10.1016/j.heliyon.2023.e13045. Epub 2023 Jan 18.
4
Interleukin-17A influences the vulnerability rather than the size of established atherosclerotic plaques in apolipoprotein E-deficient mice.白细胞介素-17A影响载脂蛋白E缺陷小鼠已形成动脉粥样硬化斑块的易损性而非大小。
Open Life Sci. 2022 Sep 8;17(1):1104-1115. doi: 10.1515/biol-2022-0072. eCollection 2022.
5
The Role of Cytokines and Chemokines in Severe Acute Respiratory Syndrome Coronavirus 2 Infections.细胞因子和趋化因子在严重急性呼吸综合征冠状病毒 2 感染中的作用。
Front Immunol. 2022 Apr 7;13:832394. doi: 10.3389/fimmu.2022.832394. eCollection 2022.
6
Can help control cytokine storm in COVID-19?能否有助于控制新冠病毒疾病中的细胞因子风暴？
J Ginseng Res. 2022 May;46(3):337-347. doi: 10.1016/j.jgr.2022.02.006. Epub 2022 Feb 25.
7
Autophagy and Mitophagy-Related Pathways at the Crossroads of Genetic Pathways Involved in Familial Sarcoidosis and Host-Pathogen Interactions Induced by Coronaviruses.自噬和线粒体自噬相关途径在家族性肉样瘤病相关遗传途径和冠状病毒引起的宿主-病原体相互作用的交汇点。
Cells. 2021 Aug 5;10(8):1995. doi: 10.3390/cells10081995.
8
A novel hypothesis for COVID-19 pathogenesis: Retinol depletion and retinoid signaling disorder.新型冠状病毒肺炎发病机制的新假说：视黄醇耗竭与维 A 酸信号紊乱。
Cell Signal. 2021 Nov;87:110121. doi: 10.1016/j.cellsig.2021.110121. Epub 2021 Aug 23.
9
The signal pathways and treatment of cytokine storm in COVID-19.新型冠状病毒肺炎中细胞因子风暴的信号通路与治疗策略。
Signal Transduct Target Ther. 2021 Jul 7;6(1):255. doi: 10.1038/s41392-021-00679-0.
10
Secukinumab in severe COVID-19 pneumonia: Does it have a clinical impact?司库奇尤单抗治疗重症新型冠状病毒肺炎：是否具有临床影响？
J Infect. 2021 Jul;83(1):e11-e13. doi: 10.1016/j.jinf.2021.05.011. Epub 2021 May 21.
J Infect. 2020 Jun;80(6):607-613. doi: 10.1016/j.jinf.2020.03.037. Epub 2020 Apr 10.
4
TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib.COVID-19 细胞因子风暴中的 TH17 反应：JAK2 抑制剂 Fedratinib 的一个新靶点。
J Microbiol Immunol Infect. 2020 Jun;53(3):368-370. doi: 10.1016/j.jmii.2020.03.005. Epub 2020 Mar 11.
5
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.中国武汉地区 2019 年新型冠状病毒感染患者的临床特征。
Lancet. 2020 Feb 15;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5. Epub 2020 Jan 24.
6
The protective and pathogenic roles of IL-17 in viral infections: friend or foe?IL-17 在病毒感染中的保护和致病作用：是敌是友？
Open Biol. 2019 Jul 26;9(7):190109. doi: 10.1098/rsob.190109. Epub 2019 Jul 24.
7
Cellular and Molecular Dynamics of Th17 Differentiation and its Developmental Plasticity in the Intestinal Immune Response.肠道免疫反应中Th17细胞分化的细胞与分子动力学及其发育可塑性
Front Immunol. 2017 Mar 31;8:254. doi: 10.3389/fimmu.2017.00254. eCollection 2017.
8
The Role of IL-17 and Related Cytokines in Inflammatory Autoimmune Diseases.白细胞介素-17及相关细胞因子在炎症性自身免疫疾病中的作用
Mediators Inflamm. 2017;2017:3908061. doi: 10.1155/2017/3908061. Epub 2017 Feb 20.